Alerta

NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS

Resumen de: AU2025255314A1

The present disclosure relates generally to novel lipids and lipid nanoparticles or their compositions for the delivery of nucleic acid therapeutics. Further, the present disclosure relates generally to methods of treating or preventing a disease comprising administering to a subject in need thereof the novel lipids and lipid nanoparticle compositions described herein.

NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS

Resumen de: AU2025254710A1

The present disclosure relates generally to novel lipids and lipid nanoparticles or their compositions for the delivery of nucleic acid therapeutics. Further, the present disclosure relates generally to methods of treating or preventing a disease comprising administering to a subject in need thereof the novel lipids and lipid nanoparticle compositions described herein.

NANOPARTICLES FOR PHOTOIMMUNE THERAPY COMPRISING PHOTOSENSITIZER AND ADJUVANT, AND USAGE THEREOF

Resumen de: US20260306632A1

0000 The present invention relates to nanoparticles, a pharmaceutical composition comprising same for preventing or treating cancer or a cell hyperplasia disorder, and the like, the nanoparticles comprising: a methylene blue-organic acid complex; a cationic adjuvant-organic acid complex; and an amphiphilic polymer, wherein the nanoparticles are an agent having excellent drug properties and permeability, and are composed only of substances in clinical use so as to have low barriers to clinical entry and high potential for commercialization. In addition, the nanoparticles make it possible to have photodynamic therapy and immunotherapy, simultaneously, and thus may be utilized in the field of preventing, ameliorating, or treating cancer or a cell hyperplasia disorder.

LIPID NANOPARTICLES FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS

Resumen de: US20260306603A1

Aspects of the present disclosure provides for improved Mycobacterium tuberculosis vaccine compositions of ionizable lipid nanoparticles for the delivery of immunogenic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in dendritic cells. In some embodiments, the incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation provided high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Other aspects of the present disclosure provide mRNA that encodes for concatenated peptides encoding for multiple MHC-II tuberculosis epitopes, and optionally includes a second mRNA encoding for concatenated MHC-I tuberculosis epitopes.

PHARMACEUTICAL COMBINATION, PREPARATION AND USES THEREOF

Resumen de: WO2026209610A1

The present invention relates to a pharmaceutical combination of i) a carrier comprising at least one pharmaceutical active compound, and ii) a nanoprimer designed to transiently occupy liver cells. The carrier is a lipid-based nanoparticle or an enveloped viral vector. The nanoprimer is a biocompatible nanoparticle designed to transiently occupy liver cells in order to potentiate the therapeutic effect of the pharmaceutical active compound transported by the carrier. Concretely, the nanoprimer is a lipid-based nanoparticle comprising an at least 50% molar ratio of anionic lipids having a phase transition temperature Tm above about -20°C and below 32°C, and having a negative surface charge value below – 10 mV and a size of about 10 nm to about 200 nm. The invention also relates to such a combination for use as a medicament in a subject in need thereof, in particular for use in the treatment of a cancer, a genetic disease, a cardiovascular disease, a brain disease, or a metabolic disease.

LIPID NANOPARTICLE-ENCAPSULATED IFNA2 NUCLEIC ACIDS FOR CANCER IMMUNOTHERAPY

Resumen de: WO2026213183A1

Disclosed herein are nanoparticulate compositions including nucleic acids, such as codon usage-optimized nucleic acids, encoding interferon alpha-2 (IFNα2) and lipid-based delivery vehicles, particularly lipid nanoparticles (LNPs). In some forms, the compositions include plasmids encoding codon usage-optimized IFNa2 mRNA molecules and/or codon usage-optimized IFNa2-encoding cDNA to express IFNα2 protein in the tumor microenvironment. Methods of treating cancer using these compositions are disclosed, wherein administration leads to increased IFNα2 expression in subjects with various cancers characterized by decreased type-1 interferon expression. In some forms, the increased IFNα2 expression is or includes increased expression in cancer cells such as those of a tumor. The therapeutic effect includes upregulation of CXCL9 and/or CXCL10 and enhanced cytotoxic T lymphocyte recruitment into the tumor microenvironment. The compositions can selectively target tumor-bearing lungs while minimizing pro-inflammatory cytokine side effects.

METHODS, COMPOSITIONS, AND USES OF PROGRAMMABLE PROTEINS FOR CELL DELIVERY

Resumen de: WO2026213035A1

Provided herein are compositions for delivering a cargo to a cell, pharmaceutical compositions comprising the same, and therapeutic methods of use thereof. Also provided are compositions and methods for mining and programing endogenous proteins to be used in delivery compositions.

LIPID NANOPARTICLES FOR THE TREATMENT OF VASCULAR DISEASES

Resumen de: AU2025251471A1

Described herein are lipid nanoparticle (LNP) formulations with demonstrated tropism towards smooth muscle cells. Also described herein are LNPs conjugated with peptides that can target tissue or cell surface receptors. The formulations of the disclosure include amounts of DOTAP, an ionizable lipid, amounts of a neutral lipid; amounts of cholesterol; and amounts of one or more PEG-lipids with preferential tropism towards vascular smooth muscle cells (vSMCs). Also described herein are peptides that target receptors highly expressed on the surface of vSMCs (1L-6R, CD63 and GAL-3) or that target proteins in the extracellular matrix adjacent to vSMCs (Col-IV) increasing the uptake into these cells.

LIPID NANOPARTICLES FOR INDUCING AN IMMUNOLOGICAL RESPONSE

Resumen de: AU2025249280A1

The present disclosure provides lipid nanoparticles that are particularly beneficial in inducing an immune response in a subject, particularly by stimulating production of antibodies by the subject. The lipid nanoparticles can include one or more of a low conjugated lipid concentration, a neutral phospholipid, and a concentration of an ionizable lipid and/or sterol that satisfy certain thresholds dependent on the conjugated lipid concentration. The disclosure also provides vaccines, other pharmaceutical compositions, and methods including the provided lipid nanoparticles.

METHODS AND MATERIALS FOR TREATING CANCER

Resumen de: US20260306684A1

This document relates to methods and materials for treating cancer. For example, this document provides vesicles (e.g., nanovesicles) designed to deliver one or more (e.g., one, two, three, or more) inhibitors to a cancer cell within a mammal (e.g., a human) having cancer to treat the mammal's cancer.

TREATMENT OF PEANUT ALLERGY WITH TOLERIZING NANOPARTICLES

Resumen de: US20260306622A1

0000 The present disclosure relates, in general to methods of treating peanut allergy using nanoparticles encapsulating peanut antigens to induce antigen-specific tolerance.

POLYMER MODIFIED NANOPARTICLES FOR CYTOKINE OR OTHER PAYLOAD DELIVERY

Resumen de: AU2025233133A1

Disclosed herein are cytokine constructs that include a delivery vehicle, and at least one cytokine or one decoy receptor. By adjusting the types and density of cytokines on the constructs, they can be tailored for both local and systemic treatment of patients with cancers and other immune-related diseases, such as autoimmune diseases. Additionally, the cytokine constructs can be used ex vivo to expand and activate cells from patients or healthy subjects before re-infusing the activated cells back into patients, which benefits adoptive and stem cell therapies. These constructs display improved half-life and stability of cytokines, enabling reducing doses, and minimizing toxicity from unintended effects of free cytokines. Furthermore, the constructs allow for co-delivery of other therapeutics, such as antibodies, small molecule inhibitors, chemotherapeutics, oligonucleotides, adjuvants, and antigens.

METHOD OF ENCAPSULATING MYCOBACTERIUM BOVIS BCG VACCINE BACILLI IN AN ALGINATE CARRIER TO COMBAT HELICOBACTER PYLORI INFECTION

Resumen de: EP4817599A1

0001 The invention relates to a method of manufacturing microparticles containing Mycobacterium bovis BCG vaccine bacilli encapsulated in an alginate carrier, intended for combating Helicobacter pylori infection, characterised in that an aqueous solution of a non-ionic copolymeric surfactant (C<3>H<6>O.C<2>H<4>O) and/or a solution of chitosan in 1% acetic acid, and a suspension of live M. bovis BCG in 1 mL of saline solution with a BCG density of 3×10<9> CFU/mL, and then subjected to a microencapsulation procedure by adding the above-mentioned solutions dropwise, using a 2 mL syringe, to a vessel containing a 0.5% calcium chloride solution, at room temperature on a magnetic stirrer for 1 hour. After one hour, the microcapsules are drained using a laboratory sieve and rinsed with sterile distilled water, using chitosans with a molecular weight in the range of 50.000-190.000 g/mol or 190.000-310.000 g/mol or 310.000-375.000 g/mol, with the concentration of the polymer solution used to prepare the alginate microcapsules being 2% v/v for alginate, 1% v/v for chitosan and 12 600 g/mol for the non-ionic copolymer surfactant (C<3>H<6>O.C<2>H<4>O)x.

親水性半導体ナノ粒子の製造方法、コンジュゲート体の製造方法、親水性半導体ナノ粒子、コンジュゲート体及び分散体

Resumen de: JP2026157925A

【課題】水系媒体中での分散安定性に優れる親水性半導体ナノ粒子を製造する方法を提供する。【解決手段】単鎖状の脂肪鎖からなる親油性配位子を半導体ナノ粒子の表面に有する疎水性半導体ナノ粒子と、脂溶性部位を有するポリエチレングリコールからなる両親媒性高分子体とを有機溶媒の中で混合することにより混合溶液を得る工程と、上記有機溶媒を揮発させるために上記混合溶液を乾燥させる工程と、上記有機溶媒を揮発させた後の結果物に水系媒体を添加して、親水性半導体ナノ粒子を上記水系媒体で分散させる工程と、を備える。上記混合溶液を乾燥させる工程では、上記混合溶液に対して３時間以下の自然乾燥を行った後に、又は、上記混合溶液に対して自然乾燥を行わずに、該混合溶液の減圧乾燥を行う、親水性半導体ナノ粒子の製造方法。【選択図】図３

NANOPARTICLES COMPRISING SIROLIMUS AND ALBUMIN, PHARMACEUTICAL COMPOSITION FOR SUBCUTANEOUS ADMINISTRATION, COMPRISING SAME, AND PREPARATION METHOD THEREFOR

Resumen de: EP4817601A1

The present disclosure relates to nanoparticles comprising sirolimus and albumin, a pharmaceutical composition for subcutaneous administration comprising the same, and a method for preparing the same. When the preparation method of the present disclosure is used, nanoparticles comprising sirolimus and albumin having excellent particle size distribution maintenance stability can be prepared, and the prepared nanoparticles can be prepared into a pharmaceutical composition suitable for subcutaneous injection, thereby improving an increase in an administration dose and the convenience of medication administration.

HYBRID PARTICLES COMPRISING A CROSS-LINKED POLYSACCHARIDE MATRIX AND METAL OXIDE NANOPARTICLES

Resumen de: WO2025114612A1

Hybrid particles comprising a cross-linked polysaccharide matrix and metal oxide nanoparticles The invention relates to a method of manufacturing hybrid particles comprising a matrix of cross-linked polysaccharide and metal oxide nanoparticles embedded therein. It has been found that hybrid particles with low polydispersity and a high load of metal oxide nanoparticles could be obtained when non-coated metal oxide nanoparticles are used. Aggregation of the non-coated metal oxide nanoparticles could be controlled to achieve said polydispersity and load. The hybrid particles of the invention, when the metal oxide is a magnetic and photothermal metal oxide, could act on the thrombosis via a combination of thermal and mechanical action, through light and magnetic stimulation, and would be targeted to the occluded vessel by an external permanent magnet.

IONIZABLE LIPID NANOPARTICLES

Resumen de: WO2025114520A1

The present invention relates to ionizable lipid nanoparticles (LNPs) including at least one lipid molecule comprising a thiourea moiety linked to a functional moiety. The ionizable lipid nanoparticles (LNPs) including at least one lipid molecule comprising a thiourea moiety linked to a functional moiety, disclosed herein, are useful in delivering an agent to a cell or in transfecting a cell, especially for gene therapy or for gene editing.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

Resumen de: WO2025117817A1

Provided are aerosolized pharmaceutical compositions including comprising aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs), the LNP comprising at least two selective organ targeting (SORT) lipids and/or at least six lipids. Also provided herein are methods of administering the aerosolized pharmaceutical compositions described herein.

CROSSLINKED POLYSACCHARIDE NANOPARTICLES

Resumen de: WO2025114613A1

Crosslinked polysaccharide nanoparticles The present invention relates to cross-linked polysaccharide nanoparticles, which can be used as drug delivery systems. The herein disclosed cross-linked polysaccharide nanoparticles are obtained via an emulsion cross-linking process. The careful choice of the surfactants used for forming the emulsion allows to reliably obtain small particles with a low polydispersity. Moreover, these particles are stable in saline solutions. The cross-linked polysaccharide nanoparticles can be loaded with proteinaceous fibrinolytic or thrombolytic agents and could be used as drug delivery systems for the treatment of thrombosis.

RADIOPAQUE NANOPARTICLES FOR MEDICAL IMAGING

Resumen de: US20250177577A1

The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.

PROCESS FOR MANUFACTURING LIPID NANOPARTICLES

Resumen de: WO2025117969A1

The present application provides methods for manufacturing lipid nanoparticles. The present disclosure provides methods of preparing empty lipid nanoparticles (empty LNPs). The present disclosure provides methods of preparing loaded lipid nanoparticles (loaded LNPs) associated with a nucleic acid. Empty and loaded LNP compositions prepared by the subject methods are also provided. There is provided a homogeneous LNP composition of empty or loaded LNPs of particularly favorable average particle size and poly dispersity index.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

Resumen de: WO2025117816A1

Disclosed herein are lipid nanoparticles (LNPS) and pharmaceutical compositions and vaccines comprising same. Also disclosed herein are methods of administering an LNP composition, pharmaceutical compositions, and vaccines described herein for preventing an infectious disease and/or for immunizing a subject or for delivering a payload to a cell in the central nervous system (CNS) of a subject. Also provided are methods for treating and/or preventing a CNS disease.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF AND METHOD FOR QUANTIFYING AN AMOUNT OF CAPPED MESSENGER RNA

Resumen de: WO2025117815A1

Provided are lipid nanoparticles compositions comprising a payload, a helper lipid, a sterol, a PEG-lipid, an ionizable lipid, a permanently cationic lipids. Also provided herein are a method of delivering a payload to a cell in a lung of a subject by intravenous administration and a method for treating and/or preventing a lung disease in a subject in need thereof by intravenous administration. Also provided are a method for quantifying an amount of capped messenger RNA (mRNA) in an mRNA sample comprising contacting the mRNA with two or more of a nuclease, an alkaline phosphatase, and a polynucleotide kinase and separating the capped mRNA and the uncapped mRNA occurs using chromatography.

GLUCOSE-TRIGGERED GELATION OF SUPRAMOLECULAR PEPTIDE NANOCOILS WITH GLUCOSE-BINDING MOTIFS

Resumen de: WO2025117822A1

Described herein are self-assembled peptides and hydrogels comprising self-assembled peptides and glucose. Exemplary hydrogels comprising self-assembled peptides and glucose may be used to encapsulate glucagon and/or a glucagon analogue. Hydrogels with glucagon and/or a glucagon analogue encapsulated therein may be used to treat hypoglycemia and related disorders in subjects in need thereof.

SUPPLEMENTATION OF LIVER ENZYME EXPRESSION

Nº publicación: EP4816000A1 07/10/2026

Solicitante:

METAGENOMI THERAPEUTICS INC [US]
Metagenomi Therapeutics, Inc.

Resumen de: WO2025117858A1

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.